Rheumatoid arthritis is a common and debilitating autoimmune disease that affects roughly 18 million people worldwide, 70% of whom are women. While current treatments can manage symptoms for many, a substantial number of patients - especially those with difficult-to-treat rheumatoid arthritis - continue to suffer from chronic inflammation and joint damage.

Cell-based therapies, including mesenchymal stromal cells (MSCs), have shown early promise in reducing inflammation and improving symptoms in both preclinical and early clinical studies. However, the efficacy of MSCs has been limited due to challenges with variability, manufacturing complexity, and suboptimal targeting of the inflammation site.

Ernexa Therapeutics’ candidate, ERNA-201, overcomes these challenges by leveraging synthetic MSCs derived from induced pluripotent stem cells (iPSCs). This engineered approach delivers the potent anti-inflammatory cytokine IL-10 directly to the site of inflammation, with superior consistency, enhanced functionality, and more precise targeting.

By resetting the inflammatory environment of the joints, ERNA-201 has the potential to provide more potent, lasting disease control for patients who need it most.